| |
|
|
|
Xtalks, Online
2025-05-16
How have recent US Food and Drug Administration (FDA) policy changes disrupted early-phase oncology trials? What innovative strategies are being used to navigate current regulatory uncertainties? How to prepare for sudden shifts in FDA guidelines, including their impact on funding challenges when moving from Phase I to Phase II?
Join an insightful webinar designed specifically for sponsors interested in mastering the complexities of early-phase oncology trials during this time of pressing uncertainty. With funding and the evolving FDA landscape making it difficult to ensure a trial’s success, this webinar will provide the necessary guidance.
This webinar is a must-attend for sponsors looking to stay ahead in the ever-changing landscape of oncology trials. Whether seeking a better understanding of non-traditional designs or solutions to achieve financial predictability during this critical phase, the expert speakers will equip attendees with the insights needed to optimize and accelerate the drug development process.
Register for this webinar today to gain insights into navigating the evolving FDA regulations and their implications for early-phase oncology trials.
Keywords: Clinical Trials, FDA, Clinical Research, FDA Approval, CRO, Oncology, Regulatory, Oncology Trials, FDA Guidance, Early-Phase Trials, Early Phase Clinical Trials, FDA Clearance
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Patrick Kelly, MD, Vice President, Medical Management, Syneos Health
XQ Xue, Vice President, Biostatistics, Syneos Health
Patrick Melvin, Vice President, Therapeutic Strategy & Innovation, Syneos Health
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-05-16
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|